CD274 and hepatocellular carcinoma: According to the results of a phase 3 trial (IMbrave 150) [3], the combination of programmed cell death-ligand 1 (PD-L1) (atezolizumab) and VEGF (bevacizumab) pathway inhibition is believed to be the most effective molecular targeted therapy for advanced HCC and is recommended as the first-line in many countries [4,5].